Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of TQF3250 Capsules in Trial Participants With Type 2 Diabetes Mellitus Complicated With Overweight or Obesity

NCT07747857 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07747857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07747857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of TQF3250 Capsules in Trial Participants With Type 2 Diabetes Mellitus Complicated With Overweight or Obesity
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 25, 2026
Completion date
July 31, 2027
Enrollment
72 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus combined with overweight or obesity